General Information of This Drug (ID: DMA4DMQ)

Drug Name
Tinostamustine   DMA4DMQ
Synonyms
Tinostamustine; EDO-S101; 1236199-60-2; EDO-S 101; EDO-S-101; Tinostamustine [USAN]; Tinostamustine(EDO-S101); 29DKI2H2NY; 7-(5-(bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide; 1H-Benzimidazole-2-heptanamide, 5-[bis(2-chloroethyl)amino]-N-hydroxy-1-methyl-; 7-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-N-hydroxyheptanamide; Minomustine; 1H-Benzimidazole-2-heptanamide, 5-(bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-; starbld0018955; UNII-29DKI2H2NY; Tinostamustine (USAN/INN); TINOSTAMUSTINE [INN]; SCHEMBL7915449; TINOSTAMUSTINE [WHO-DD]; CHEMBL3989941; BCP20331; EX-A1322; BDBM50569838; AKOS030526024; CS-6484; DB15147; SB19172; BE170657; MS-27198; HY-101780; S8769; D11182; E76854; 7-{5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}-N-hydroxyheptanamide
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Phase 1/2 [1]
Drug Type
Small molecule
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Tinostamustine + Panobinostat DCFUKZ9 Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03687125) Phase 1/2 Open-label Trial of Tinostamustine Conditioning and Autologous Stem Cell Transplantation for Salvage Treatment in Relapsed / Refractory Multiple Myeloma (TITANIUM 1). U.S.National Institutes of Health.
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.